EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Large Congenital Melanocytic Nevus With LMNA :: NTRK1 Fusion: Expanding Targeted Therapy Options for Congenital Nevi and Melanoma

Akanksha Nagarkar, Jackson Turbeville, Molly A Hinshaw iD, Philip E LeBoit, Jeffrey Gagan, Mark Raffeld, Kenneth Aldape, Niharika Shah, Frederic G Barr, Liqiang Xi, Ina Lee, Christina K Ferrone und 5 weitere

Journal of Cutaneous Pathology · 2025

DOI: 10.1111/cup.14822 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cutaneous Pathology, 2025. Verfasst von Akanksha Nagarkar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States. Hauptthemen laut MEDLINE: Lamin Type A, Nevus, Pigmented, Oncogene Proteins, Fusion, Receptor, trkA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Large congenital melanocytic nevi/nevus (LCMN) are caused by genetic events that activate the mitogen‐activated protein kinase (MAPK) and extracellular signal‐regulated kinase (ERK) pathway. Individuals with LCMN are prone to developing aggressive melanomas during childhood. Targeted therapies are needed to treat this form of melanoma and manage LCMN symptoms such as pruritus and pain, which significantly impact quality of life. Here, we present the first case of an LCMN with an NTRK fusion driver event. The patient presented with an atypical proliferative nodule arising in the background nevus. RNA sequencing of the proliferative nodule with background nevus identified a pathogenic LMNA::NTRK1 fusion. The fusion resulted in constitutive expression of TrkA, demonstrated by strong cytoplasmic pan‐TRK staining, along with activation of the MAPK/ERK pathway, as indicated by positive nuclear and cytoplasmic staining for phosphorylated ERK. The background nevus beneath the proliferative nodule also expressed pan‐TRK and phosphorylated ERK, suggesting that the NTRK1 fusion occurred prior to the formation of the proliferative nodule. This case broadens the spectrum of driver events for LCMN and suggests that screening for TRK fusions in LCMN should be considered when systemic therapy is being considered for melanoma or symptom management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lamin Type ANevus, PigmentedOncogene Proteins, FusionReceptor, trkASkin NeoplasmsHumansMAP Kinase Signaling System

Stichwörter der Autor:innen

NTRK fusioncongenital melanocytic nevimelanomanevusproliferative nodule

Substanzen

Lamin Type ALMNA protein, humanNTRK1 protein, humanOncogene Proteins, FusionReceptor, trkA

Autor:innen und Institutionen

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States.
  • Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States.
  • Dermatology and Pathology, Helen Diller Family Cancer Center, University of California, San Francisco, California, United States.
  • Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.
  • Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.
  • Laboratory of Cell and Developmental Signaling, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States.

ORCID-Profile: Molly A Hinshaw

Förderung

  • Intramural NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Nagarkar, A., Turbeville, J., Hinshaw, M. A., LeBoit, P. E., Gagan, J., Raffeld, M., Aldape, K., Shah, N., Barr, F. G., Xi, L., Lee, I., Ferrone, C. K., Pack, S. D., Kaplan, R., Malone, M. F. W., Yohe, M., & Sargen, M. R. (2025). Large Congenital Melanocytic Nevus With LMNA :: NTRK1 Fusion: Expanding Targeted Therapy Options for Congenital Nevi and Melanoma. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14822

Vancouver

Nagarkar A, Turbeville J, Hinshaw MA, LeBoit PE, Gagan J, Raffeld M, et al. Large Congenital Melanocytic Nevus With LMNA :: NTRK1 Fusion: Expanding Targeted Therapy Options for Congenital Nevi and Melanoma. Journal of Cutaneous Pathology. 2025. doi:10.1111/cup.14822

BibTeX
@article{Nagarkar2025,
  author = {Nagarkar, Akanksha and Turbeville, Jackson and Hinshaw, Molly A and LeBoit, Philip E and Gagan, Jeffrey and Raffeld, Mark and Aldape, Kenneth and Shah, Niharika and Barr, Frederic G and Xi, Liqiang and Lee, Ina and Ferrone, Christina K and Pack, Svetlana D and Kaplan, Rosandra and Malone, Mary Frances Wedekind and Yohe, Marielle and Sargen, Michael R},
  title = {Large Congenital Melanocytic Nevus With LMNA :: NTRK1 Fusion: Expanding Targeted Therapy Options for Congenital Nevi and Melanoma},
  journal = {Journal of Cutaneous Pathology},
  year = {2025},
  doi = {10.1111/cup.14822}
}
Kostenlos starten →